Recursion (RXRX) CFO: RSU Tax Withholding Reduces Shares by 7,057 at $4.83

Rhea-AI Filing Summary

Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.

Positive

• Clear disclosure that the transaction was an issuer withholding related to RSU net settlement
• Substantial remaining ownership of 804,169 shares after the withholding, indicating continued alignment with shareholders

Negative

• 7,057 shares were disposed (withheld) to satisfy tax obligations, reducing the reporting person's holdings
• Transaction price of $4.83 per share indicates the withholding occurred at that price level

Insights

Securities Analyst

TL;DR: Routine issuer tax-withholding reduced the CFO's share count by a small amount; large remaining ownership suggests continued alignment with shareholders.

The transaction is categorized as an issuer withholding to cover tax obligations from restricted stock unit net settlement, not an open-market disposition. With 804,169 shares reported after the withholding, the reporting person retains a substantial beneficial position. The withheld quantity, 7,057 shares, is immaterial relative to the post-transaction holdings and appears administrative.

Corporate Governance Expert

TL;DR: Administrative equity withholding for taxes is standard; disclosure is compliant and provides transparency on insider holdings.

The form discloses the nature of the withholding and the resulting beneficial ownership, meeting Section 16 transparency requirements. There is no indication of a change in overall ownership control or of a voluntary sale by the officer. Documentation of the withholding mechanism is helpful for governance record-keeping.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/15/2025		F(1)		7,057	D	$4.83	804,169	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the Recursion Pharmaceuticals (RXRX) insider report on Form 4?

The CFO reported an issuer withholding of 7,057 Class A shares related to net settlement of restricted stock units to satisfy tax withholding.

How many shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owns 804,169 Class A shares following the reported withholding.

Was the Form 4 transaction an open-market sale or an issuer withholding?

The filing identifies the transaction as an issuer withholding tied to RSU net settlement, not an open-market sale.

What price per share is shown for the withheld shares?

The withheld shares are reported at a price of $4.83 per share.

Which reporting person is identified on the Form 4?

The reporting person is listed as Ben R. Taylor, identified as the company's Chief Financial Officer.

Does the Form 4 show any derivative transactions or option activity?

No derivative securities or option exercises are reported; only a non-derivative withholding of Class A common stock is shown.